An office of the U.S. Food and Drug Administration (FDA has recommended that belantamab mafodotin, GlaxoSmithKline’s investigational antibody-drug conjugate, be approved for heavily pretreated relapsed or refractory multiple myeloma patients. The recommendation by the FDA’s Oncologic Drugs Advisory Committee is for patients who had at least four prior lines of treatment, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody. If approved, belantamab mafodotin will be the first therapy of its class available for advanced multiple…
You must be logged in to read/download the full post.
The post FDA Office Favors Antibody-drug Conjugate for Advanced Multiple Myeloma appeared first on BioNewsFeeds.